Epstein-Barr virus serology in the control of nasopharyngeal carcinoma

Epstein-Barr virus (EBV) is suspected as being etiologically related to nasopharyngeal carcinoma (NPC). Antibodies to EBV antigens have been used in the early detection of NPC and serologic assays are being utilized in the mass screening of high risk populations. While areas of potential application to disease control, such as therapy, are still in the developmental phase, EBV serology has been reported to be of value in the detection of early relapse. Since the data from a series of studies provide conflicting results, however, in this report we review the current information regarding detection of early relapse and describe specific areas that require particular attention if the role of EBV serology in this aspect of NPC control is to be well defined.